BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16280454)

  • 1. Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards.
    Zhang D; Zhang H; Aranibar N; Hanson R; Huang Y; Cheng PT; Wu S; Bonacorsi S; Zhu M; Swaminathan A; Humphreys WG
    Drug Metab Dispos; 2006 Feb; 34(2):267-80. PubMed ID: 16280454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection.
    Wang L; Zhang D; Swaminathan A; Xue Y; Cheng PT; Wu S; Mosqueda-Garcia R; Aurang C; Everett DW; Humphreys WG
    Drug Metab Dispos; 2006 Mar; 34(3):427-39. PubMed ID: 16381667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
    Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG
    Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and disposition of 14C-labeled peliglitazar in humans.
    Wang L; Munsick C; Chen S; Bonacorsi S; Cheng PT; Humphreys WG; Zhang D
    Drug Metab Dispos; 2011 Feb; 39(2):228-38. PubMed ID: 20978103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment.
    Zhang D; Raghavan N; Wang L; Xue Y; Obermeier M; Chen S; Tao S; Zhang H; Cheng PT; Li W; Ramanathan R; Yang Z; Humphreys WG
    Drug Metab Dispos; 2011 Jan; 39(1):123-31. PubMed ID: 20876787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
    Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
    Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
    Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 96-well single-pot liquid-liquid extraction, hydrophilic interaction liquid chromatography-mass spectrometry method for the determination of muraglitazar in human plasma.
    Xue YJ; Liu J; Unger S
    J Pharm Biomed Anal; 2006 Jun; 41(3):979-88. PubMed ID: 16533587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology.
    Yao M; Swaminathan A; Srinivas N
    Biopharm Drug Dispos; 2007 Jan; 28(1):35-42. PubMed ID: 17117455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
    Colizza K; Awad M; Kamel A
    Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass defect filtering on high resolution LC/MS data as a methodology for detecting metabolites with unpredictable structures: identification of oxazole-ring opened metabolites of muraglitazar.
    Zhang D; Cheng PT; Zhang H
    Drug Metab Lett; 2007 Dec; 1(4):287-92. PubMed ID: 19356057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization to eliminate the interference of migration isomers for measuring 1-O-beta-acyl glucuronide without extensive chromatographic separation.
    Xue YJ; Akinsanya JB; Raghavan N; Zhang D
    Rapid Commun Mass Spectrom; 2008; 22(2):109-20. PubMed ID: 18059002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
    Balani SK; Xu X; Pratha V; Koss MA; Amin RD; Dufresne C; Miller RR; Arison BH; Doss GA; Chiba M; Freeman A; Holland SD; Schwartz JI; Lasseter KC; Gertz BJ; Isenberg JI; Rogers JD; Lin JH; Baillie TA
    Drug Metab Dispos; 1997 Nov; 25(11):1282-7. PubMed ID: 9351905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma.
    Yao M; Srinivas N
    Biomed Chromatogr; 2006 Oct; 20(10):1017-23. PubMed ID: 16506266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 96-well single-pot protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of muraglitazar, a novel diabetes drug, in human plasma.
    Xue YJ; Liu J; Pursley J; Unger S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):213-22. PubMed ID: 16388995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.
    Dow J; Piriou F; Wolf E; Dulery BD; Haegele KD
    Drug Metab Dispos; 1994; 22(5):738-49. PubMed ID: 7835226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.